|
|
 | | | |
- close
- close
- close
- close
These excerpts taken from the CELG 10-K filed Feb 20, 2008. COMPETITION
The pharmaceutical and biotechnology industries in which we
compete are each highly competitive. Our competitors include
major pharmaceutical and biotechnology companies, many of which
have considerably greater financial, scientific, technical and
marketing resources than us. We also experience competition in
the development of our products and processes from universities
and other research institutions and, in some instances, compete
with others in acquiring technology from such sources.
Competition in the pharmaceutical industry, and specifically in
the oncology and immune-inflammatory areas being addressed by
us, is particularly intense. Numerous pharmaceutical,
biotechnology and generic companies have extensive anti-cancer
and anti-inflammatory drug discovery, development and commercial
resources. Bristol-Myers Squibb Co., Amgen Inc., Genentech,
Inc., Sanofi-Aventis SA., Novartis AG, AstraZeneca PLC., Eli
Lilly and Company, F. Hoffmann-LaRoche Ltd, Millennium
Pharmaceuticals, Inc., Eisai Co., Ltd., Biogen Idec Inc., Merck
and Co., Inc., Johnson and Johnson and Pfizer Inc. are among
some of the companies researching and developing new compounds
in the oncology, inflammation and immunology fields.
The pharmaceutical and biotechnology industries have undergone,
and are expected to continue to undergo, rapid and significant
technological change. Also, consolidation and competition are
expected to intensify as technical advances in each field are
achieved and become more widely known. In order to compete
effectively, we will be required to continually upgrade and
expand our scientific expertise and technology, identify and
retain capable personnel and pursue scientifically feasible and
commercially viable opportunities.
Our competition will be determined in part by the indications
and geographic markets for which our products are developed and
ultimately approved by regulatory authorities. An important
factor in competition will be the timing of market introduction
of our or our competitors’ products. Accordingly, the
relative speed with which we can develop products, complete
clinical trials and regulatory approval processes, receive
pricing and reimbursement in certain markets and supply
commercial quantities of products to the market are expected to
be important competitive factors. Competition among products
approved for sale will be based, among other things, on product
efficacy, safety, convenience, reliability, availability, price,
third-party reimbursement and patent and non-patent exclusivity.
Table of Contents
COMPETITION The pharmaceutical and biotechnology industries in which we compete are each highly competitive. Our competitors include major pharmaceutical and biotechnology companies, many of which have considerably greater financial, scientific, technical and marketing resources than us. We also experience competition in the development of our products and processes from universities and other research institutions and, in some instances, compete with others in acquiring technology from such sources. Competition in the pharmaceutical industry, and specifically in the oncology and immune-inflammatory areas being addressed by us, is particularly intense. Numerous pharmaceutical, biotechnology and generic companies have extensive anti-cancer and anti-inflammatory drug discovery, development and commercial resources. Bristol-Myers Squibb Co., Amgen Inc., Genentech, Inc., Sanofi-Aventis SA., Novartis AG, AstraZeneca PLC., Eli Lilly and Company, F. Hoffmann-LaRoche Ltd, Millennium Pharmaceuticals, Inc., Eisai Co., Ltd., Biogen Idec Inc., Merck and Co., Inc., Johnson and Johnson and Pfizer Inc. are among some of the companies researching and developing new compounds in the oncology, inflammation and immunology fields. The pharmaceutical and biotechnology industries have undergone, and are expected to continue to undergo, rapid and significant technological change. Also, consolidation and competition are expected to intensify as technical advances in each field are achieved and become more widely known. In order to compete effectively, we will be required to continually upgrade and expand our scientific expertise and technology, identify and retain capable personnel and pursue scientifically feasible and commercially viable opportunities. Our competition will be determined in part by the indications and geographic markets for which our products are developed and ultimately approved by regulatory authorities. An important factor in competition will be the timing of market introduction of our or our competitors’ products. Accordingly, the relative speed with which we can develop products, complete clinical trials and regulatory approval processes, receive pricing and reimbursement in certain markets and supply commercial quantities of products to the market are expected to be important competitive factors. Competition among products approved for sale will be based, among other things, on product efficacy, safety, convenience, reliability, availability, price, third-party reimbursement and patent and non-patent exclusivity.
Table of Contents | EXCERPTS ON THIS PAGE:
RELATED TOPICS for CELG: |
| |||||||
